Although the revenue and EPS for UiPath (PATH) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
UiPath (PATH) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.09 per share a year ago.
UiPath also raised its guidance and approved a half a billion stock buyback program.
There are key questions around UiPath that investors don't have the answers to yet. The company is in a good position to capture the upside in a promising space, which might motivate some investors to buy before they have those answers.
Evaluate the expected performance of UiPath (PATH) for the quarter ended July 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
UiPath faces significant challenges, and its stock price reflects them. Leadership changes and solid financial metrics could pave the way to a recovery.
UiPath is a leader in business process automation that is well positioned for growth ahead of a $60 billion opportunity. Upstart Holdings has made significant improvements to its AI lending models that are starting to show in its financial results.
UiPath stock is down 45% this year.
Given the recent decline in UiPath's stock price, we analyze its current position to determine whether it is a worthwhile investment.
In the most recent trading session, UiPath (PATH) closed at $12.64, indicating a +1.85% shift from the previous trading day.
Zacks.com users have recently been watching UiPath (PATH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
UiPath Inc. NYSE: PATH is a leading provider of robotic process automation and business process automation software. Rather than physical robots, UiPath utilizes software robots (bots) to automate repetitive, rule-based tasks usually performed by humans.